NCT02776137View on ClinicalTrials.gov

Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

February 28, 2019

Conditions

Head-and-neck CancerSquamous Cell Carcinoma

Interventions

DRUG

Docetaxel

Docetaxel: 20mg/m2/w for 6 weeks

RADIATION

Intensity-modulated radiotherapy

a total dose of 60Gy in 30 fractions over 6 weeks

Trial Locations (1)

200011

Shanghai ninth people's hospital, Shanghai

All Listed Sponsors

lead

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

OTHER

NCT02776137 - Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck | Biotech Hunter | Biotech Hunter